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Abstract
NGAL/lipocalin-2 is a siderophore-binding protein that is highly expressed in several cancers. It is suggested to confer a
proliferative advantage to cancer cells. Its expression has been correlated with aggressiveness of breast cancer as
determined both in patients and in mouse breast cancer models. This was recently confirmed in two mouse models of
spontaneous breast cancer in wild-type and lipocalin-2-deficient mice. We used a similar strategy using a different mouse
strain. Lipocalin-2-deficient mice and mouse mammary tumor virus-polyoma middle T antigen (MMTV-PyMT) mice were
crossed into the same FVB/N background. All mice developed tumors by week 8. The mice were sacrificed on week 13 and
tissue was processed for biochemical and histological analysis. The total tumor volume and number of metastases were
quantitated in 26 lipocalin-2-deficient mice and 34 wild-type controls. Lipocalin-2 expression in tumors of MMTV-PyMT-
positive and wild-type mice was assessed by quantitative real-time PCR and by immunohistochemistry. The expression of
the lipocalin-2 receptors 24p3R and megalin and of Mmp-9, transferrin receptor, and Bdh2 (a producer of a mammalian
siderophore) were quantitated by real-time PCR. No significant difference was observed between wild-type and lipocalin-2-
deficient mice. Lipocalin-2 was highly expressed in tumors from wild-type mice, but the expression did not correlate with
tumor size. No effect of lipocalin-2 was observed with respect to time to tumor appearance, total tumor volume, or to the
number of metastases. Histology and gelatinolytic activity of the mammary tumors did not differ between wild-type and
lipocalin-2-deficient mice. We conclude that NGAL/lipocalin-2 does not invariably affect the aggressiveness of breast cancers
as assessed in mouse models, thus questioning the role of lipocalin-2 in cancer development.
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Introduction
NGAL, neutrophil gelatinase associated lipocalin, was so named
by its discoverers as a lipocalin present in human neutrophil
specific granules, in part covalently associated with gelatinase B/
matrix metalloproteinase-9 (MMP-9) [1,2]. Highly homologous
proteins are found in other species such as exFAB in fowls [3] and
neu-related lipocalin induced in rat mammary tumors by the neu
oncogene [4]. The mouse orthologue was identified as an
oncogene and termed 24p3 [5] but has also been termed major
urinary protein [6] and siderocalin [7]. These different names are
united in the term lipocalin-2 encoded by the LCN2/Lcn2 gene in
man and mouse, respectively.
Soon after the discovery of lipocalin-2 as a constituent of neutrophil
specific granules, lipocalin-2 was found to be highly up-regulated in
epithelial cells at sites of inflammation [8–10] and to be highly
expressed in some cancers [4,11–13]. Lipocalin-2 has also received
significant attention as an early and sensitive marker of damage to
kidney tubule epithelial cells [14–17]. A function of lipocalin-2 in the
innate immune defense against bacteria was demonstrated shortly after
the discovery of lipocalin-2 as a siderophore-binding protein [7,18,19],
as mice deficient in lipocalin-2 are more susceptible to infections by E.
coli [20–22], K. pneumonia [23], and M. tuberculosis [24,25] than their
wild-type litter controls.
Lipocalin-2 has been inferred as an important regulator of
apoptosis in myeloid cells [26]. This is claimed to depend on the
ability of cells to take up lipocalin-2 via the 24p3-receptor [27]. Such
uptake would result in apoptosis if lipocalin-2 is iron-deplete and
promote growth if lipocalin-2 is iron-replete. The bacterial enzyme
Ent A synthesizes the siderophore constituent 2,3-dihydroxy
benzoic acid (DHBA). A mammalian homologue named BDH2
was recently described which generates 2,5-DHBA, the long sought
for endogenous siderophore responsible for lipocalin-2 mediated
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iron trafficking in mammalian cells [28]. Catechol, a metabolite of
tyrosine and other organic compounds, was identified as an
alternative endogenous siderophore candidate [29]. The role of
lipocalin-2 in controlling myeloid cell apoptosis is, however,
questioned by the lack of obvious alterations in myelopoiesis of
lipocalin-2-deficient mice [21] and by in vitro studies of the effect of
lipocalin-2 on isolated human myeloid cells [30].
The involvement of lipocalin-2 in tumor genesis has particularly
been studied in breast cancer, where lipocalin-2 (NGAL)
expression is associated with poor prognosis in human primary
breast cancer [31] and an increased urinary level of lipocalin-2
correlates with aggressiveness of the cancer [32]. The proposed
mechanisms by which lipocalin-2 promotes growth and metastasis
of breast cancer cells are multiple. Association of lipocalin-2 with
MMP-9 was shown to induce allosteric activation of the enzymatic
activity of MMP-9 and to protect MMP-9 from autodegradation
[33,34]. Lipocalin-2 has also been inferred as a direct regulator of
expression of pro-oncogenic factors necessary for mesenchymal
transition [32].
In order to directly address the role of lipocalin-2 in
development of breast cancer, we initiated a study examining
the role of lipocalin-2 in the spontaneous mouse mammary tumor
virus-polyoma middle T antigen (MMTV-PyMT) mouse model.
Since the genetic background influences the development of tumor
growth and metastasis in MMTV-PyMT transgenic mice, we chose
to use highly inbred mice from the FVB/N strain and
heterozygous breeding to generate minimal genetic variation in
order to detect even minor effects of lipocalin-2 in cancer
development, a model that has been very useful in previous
studies [35–37]. While our study was ongoing, two reports have
appeared using the same or similar strategies [38,39]. While major
differences in the role of lipocalin-2 on tumor progression and
metastasis was observed in these two studies, both confirmed that
lipocalin-2 is associated with tumor progression and that complex
formation with MMP-9 seems to be part of the mechanism. Our
study used the same MMTV-PyMT mouse model as Berger et al.
[38], but the results differ substantially, as we do not observe any
significant effect of lipocalin-2 on any parameter associated with
tumor growth and metastasis despite a brisk up-regulation of
lipocalin-2 in the breast cancer cells. In addition, our study
addresses whether the lipocalin-2 receptors and Bdh2 are
expressed in the tumors.
Materials and Methods
Ethics statement
All animal experiments were conducted at The Department of
Experimental Medicine, University of Copenhagen and National
University Hospital, Rigshospitalet, Copenhagen, Denmark, in
accordance with both institutional and national guidelines (Danish
Animal Experiments Inspectorate, permission number 2007/561–
1353). The review board at the Faculty of Health Science,
University of Copenhagen, approved this study (P0599). An
observer unaware of the genotypes of the mice performed all
experimental evaluations. The mice were inspected daily and
palpated once a week. No experiments were performed on live
mice. Humane endpoint was set at tumor size influencing the
general well being or behavior of the mice.
Mice breeding
Congenic heterozygous male FVB/N-MMTV-PyMT mice were
mated with heterozygous female Lcn2 knock-out mice (Lcn2+/2)
[20] that had been back-crossed to the FVB/N strain for 8
generations (N8). Their male FVB/N-PyMT, Lcn2+/2 offspring
(F1) were mated with FVB/N-Lcn2+/2 (N9) females to generate the
PyMT, Lcn2+/+ (n = 34); PyMT, Lcn22/2 (n = 26); Lcn2+/+ (n = 5),
and Lcn22/2 (n = 7) mice used throughout the study (Figure S1).
Quantification of primary tumors
Mice were examined weekly for mammary tumor onset by
palpation for nodules in all 10 mammary glands. Tumor volume
was assessed by measuring the length (L) and width (W) of
individual tumors with a caliper and calculated by the formula
V(tumor) = p L W2/6 [40]. The individual tumor volumes were
summed to give the total tumor volume in each mouse.
Tissue processing
Mice were anaesthetized by intraperitoneal administration of
1:1 mixture of Hypnorm (Janssen-Cilag Ltd) and Midazolam
(Roche) and tissue fixated by intracardial perfusion with 10 ml
cold PBS followed by 10 ml of freshly prepared PBS with 4%
paraformaldehyde (PFA). A blood sample was obtained by heart
puncture prior to perfusion-fixation and EDTA-plasma was
isolated by centrifugation (2000 g, 30 minutes, 4uC) and stored
at 220uC. The tumor located in the fourth breast gland on the left
hand side was excised prior to PFA perfusion and stored at 280uC
for later RNA purification or extraction for western blotting and
zymography. Following PFA perfusion, the corresponding tumor
on the right hand side was placed in PFA for paraffin embedding
and histological examination. The lungs were removed and placed
in PFA for further fixation followed by processing and immuno-
histochemical staining as described in [41].
Quantification of metastases
The volume of metastases in lungs was determined by a
computer-assisted stereological method on hematoxylin eosin-
stained sections of the lungs as described previously in [42].
Immunohistochemical staining
Immunohistochemical detection of lipocalin-2 and MMP-9 was
performed as described in [22]. Antibodies used were goat anti-
mouse lipocalin-2 (1:100, AF1857, R&D Systems) and rabbit anti-
mouse MMP-9 (1:2000, ab38898, Abcam). Immunohistochemical
staining of formalin-fixed paraffin-embedded primary tumors for
E-cadherin, vimentin, and alpha smooth muscle actin (a-SMA)
was performed using the following antibodies: Rabbit anti-mouse
E-cadherin (1:500, ab53033, Abcam), rabbit anti-mouse Vimentin
(1:500, ab92547, Abcam), and rabbit anti-mouse a-SMA (1:500,
ab5694, Abcam). The specimens for this procedure were selected
among PyMT, Lcn2+/+ and PyMT, Lcn22/2 mice with large and
small total volumes of primary tumors, large, intermediate, and
small total volumes of metastases, and among mice with large,
intermediate, and small numbers of metastases respectively. In
total 16 specimens of primary tumors underwent immunohisto-
chemical staining for E-cadherin, vimentin, and a-SMA. Sections
of primary tumors were deparaffinized, hydrated, and antigen
retrieval was performed by 10 minutes incubation with proteinase
K at 37uC for E-cadherin-staining and 10 minutes of heating at
98uC in citrate buffer, pH 6 for vimentin and a-SMA staining.
Endogenous peroxidase activity was blocked with 1% H2O2.
Sections were incubated overnight with primary antibodies diluted
in Dako Antibody Diluent (S3022, Dako). Sections were subse-
quently incubated for 45 minutes with secondary antibody,
EnVision+-System HRP-Labelled Polymer Anti-rabbit (K4003,
Dako), developed with Vector NovaRED (SK-4800, VWR
International), counterstained with Mayer’s Hematoxylin, and
finally dehydrated and mounted. The slides were examined under
Lipocalin-2 in Mouse Breast Cancer
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a BX51 microscope (60x/1.40 PlanApo oil objective) with
Olympus DP70 photo system and analySIS software 5.0
(Olympus) or Leica DM 2500 microscope with Leica DFC 425
camera and software.
Histology
The tumors were diagnosed on coded specimens using the
classification of PyMT tumors by Lin et al. [43], and employed by
Almholt et al. [44]. In short, the four tumor stages are:
Hyperplasia, Adenoma, Early Carcinoma, and Late Carcinoma.
Figure 1. Histological characterization of mammary tumors. A, C, E, immunohistochemical staining for lipocalin-2 in mammary tumor in (A)
PyMT, Lcn2+/+ mouse, (C) PyMT, Lcn22/2, and (E) PyMT, Lcn2+/+ mouse as negative control, where no primary antibody was added. B, D, F,
immunohistochemical staining for MMP-9 in mammary tumor in (B) PyMT, Lcn2+/+ mouse, (D) PyMT, Lcn22/2, and (F) PyMT, Lcn2+/+ mouse as
negative control, where no primary antibody was added. Original magnification x600. G, H+E staining of tumor from a PyMT, Lcn2+/+ mouse
representing largest metastasis volume. F, H+E staining of tumor from PyMT, Lcn22/2 mouse representing largest metastasis volume. In both G and
F strongly atypical tumor cells with numerous mitoses are seen, and surrounded by slender strands of collagen tissue. Original magnification x630.
Abbreviations: PyMT: MMTV-PyMT.
doi:10.1371/journal.pone.0039646.g001
Lipocalin-2 in Mouse Breast Cancer
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The patterns of stromal formation were also recorded. Evaluation
of sections stained for E-cadherin, vimentin, and a-SMA were
evaluated on coded specimens.
Isolation of murine granulocytes for Western blot
Two FVB/N wild-type mice were euthanized by cervical
dislocation and the spleens were removed and homogenized in
PBS with 4% fetal calf serum (FCS) with a mortar and a pestle.
The homogenate was filtered through a 70 mm nylon mesh
(352350, BD Biosciences) and kept on ice. Following centrifuga-
tion (300 g for 4 minutes, 4uC), the supernatant was removed and
the pellet resuspended in Pharm Lyse (BD Biosciences) for lysis of
erythrocytes. Lysis was terminated by addition of PBS with 4%
FCS and the cells were pelleted by centrifugation (300 g for
4 minutes, 4uC) and subsequently resuspended in PBS with 4%
FCS. Granulocytic cells were isolated by immunomagnetic sorting
using the magnetic-activated cell sorting (MACS) system and Gr-
1-Biotin antibody (130-092-332, Miltenyi or 51-01212J, BD
Pharminogen) according to the manufacturer’s instructions
(Miltenyi). Separation was performed on a MACS LS column
(Miltenyi).
Figure 2. Representative immunohistochemical stainings of mammary tumors. A, staining for E-cadherin in a PyMT, Lcn2+/+ mouse. B,
staining for E-cadherin in a PyMT, Lcn22/2 mouse. C, staining for a-SMA in a PyMT, Lcn2+/+ mouse. D, staining for a-SMA in a PyMT, Lcn22/2 mouse.
E, staining for vimentin in a PyMT, Lcn2+/+ mouse. F, staining for vimentin in a PyMT, Lcn22/2 mouse. Original magnification x400. Abbreviations:
PyMT: MMTV-PyMT. a-SMA: Alpha smooth muscle actin.
doi:10.1371/journal.pone.0039646.g002
Lipocalin-2 in Mouse Breast Cancer
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Preparation of human samples for Western blot
Granulocytes were isolated from peripheral blood by use of
Lymphoprep (Axis-Shield PoC AS) and treated with 5 mM di-
isopropyl fluorophosphate (Calbiochem). Granulocytes were
resuspended in disruption buffer (100 mM KCL, 1 mM Na2ATP,
3.5 mM MgCl2, 10 mM PIPES, pH 7.2) with 0.5 mM phenyl-
methylsulfonylfluoride (PMSF) added. Cells were disrupted by
nitrogen cavitation at 600 psi for 5 minutes and collected in
1.5 mM EGTA [45,46]. The cavitate was centrifuged at 400 g for
15 minutes to remove nuclei and unbroken cells. The supernatant
(S1), which contains the granules, was analyzed further by Western
blot as described below.
Tumor extraction
Four large tumors from PyMT, Lcn2+/+ mice and four tumors
of corresponding sizes from PyMT, Lcn22/2 mice were selected
for extraction. The tumors were kept on ice and homogenized
with a blender in 5 ml of lysis buffer (150 mM NaCl, 50 mM
Trizma base, 0.5% deoxycholic acid, 0.1% SDS, 1% NP-40) per
mg weight of tissue. After 15 minutes of incubation on ice the
Table 1. Histological diagnoses of H+E-stainings of the breast tumors.
Selection criteria Histology, wild type Histology, knock out
Largest total volume of primary tumors LC LC
Smallest total volume of primary tumors LC LC
Largest number of metastases LC LC
Smallest number of metastases LC EC
Largest total volume of metastases LC LC
Smallest total volume of metastases LC LC
Tumors diagnosed were selected by the above listed criteria.
LC = Late Carcinoma EC = Early Carcinoma.
doi:10.1371/journal.pone.0039646.t001
Figure 3. Growth of primary tumors in PyMT, Lcn2+/+ and PyMT, Lcn22/2 mice. A, Lcn2-deficiency has no effect on tumor onset. Data shown
are percentage of mice without palpable mammary tumors on the indicated weeks visualized by a Kaplan-Meier plot. Curves did not differ statistical
significantly, log-rank test, p = 0.57 (n = 33 for PyMT, Lcn2+/+ and n = 25 for PyMT, Lcn22/2). B, average of total volume of mammary tumors versus
age. No statistical significant difference between PyMT, Lcn2+/+ and PyMT, Lcn22/2 mice at week 13, t-test after logarithmic transformation, p = 0.21
(n = 29 for PyMT, Lcn2+/+ and n = 19 for PyMT, Lcn22/2). C, numbers of tumor positive glands per mouse as determined by palpation at week 10
where the first mouse out of all the mice presents with all mammary glands tumor positive. No significant difference in tumor positive mammary
glands, Mann-Whitney U-test, P = 0.85 (n = 33 for PyMT, Lcn2+/+ and n = 25 for PyMT, Lcn22/2). Horizontal bars indicate medians. Abbreviations:
PyMT: MMTV-PyMT.
doi:10.1371/journal.pone.0039646.g003
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tumor suspensions were centrifuged at 13.500 rpm for 10 minutes
at 4uC and the supernatants were collected and stored at 220uC.
Western blot
The samples were diluted in sample buffer with or without
reducing agents and boiled for 5 minutes. Electrophoresis was
performed according to standard procedures on a 4–12% Nu Page
Bis-Tris gradient gel (Invitrogen) as described in [22]. The
antibodies used were goat anti-mouse lipocalin-2 (1:1000,
AF1857, R&D Systems), rabbit anti-mouse MMP-9 (1:5000,
ab38898, Abcam), mouse anti-human lipocalin-2 (1:1000, [47]) or
rabbit anti-human MMP-9 (1:1000, [46]), followed by HRP-
conjugated secondary antibodies: Rabbit anti-goat (1:1000, P0449,
Dako), goat anti-rabbit (1:1000, P0448, Dako), or rabbit anti-
mouse (1:1000, P0260, Dako). The membranes were developed by
chemiluminescence using SuperSignal West Pico Chemilumines-
cence Substrate (Pierce) according to the manufacturer’s instruc-
tion and analyzed on a Bio-Rad Chemidoc (Bio-Rad).
Zymography
Samples in 4% glycerol, 1% SDS, 0.125% bromophenol blue,
125 mM Tris-HCl, pH 6.8 were loaded on precast 10%, 1 mm
gelatin zymogram gels (Novex Invitrogen EC61752 BOX) and run
at 25 mA, washed in 2.5% Triton X-100, 20 mM Tris-HCl
pH 7.8, 5 mM CaCl2, 1 mM ZnCl2, incubated with shaking for
1 hour in the same buffer, washed 3 times in H2O, incubated
overnight at 37uC in 50 ml 1% Triton X-100, 20 mM Tris-HCl
pH 7.8, 5 mM CaCl2, 1 mM ZnCl2, stained for 30 min in 0.5%
Coomassie, 10% acetic acid 30% ethanol, and destained in 10%
acetic acid, 30% ethanol. For inhibition of metalloproteinase
activity, 5 mM EDTA and 2 mM 1,10-phenantroline were added
during the overnight incubation [48].
RNA purification and quantification
Tumors were homogenized and suspended in TRIzol Reagent
(Invitrogen) for RNA isolation according to the manufacturer’s
instruction. mRNA expression was determined by real-time PCR
using the TaqMan method as described in [9]. The FAM-labeled
probes used were Lcn2: Mm01324470_m1, Mmp9:
Mm00600164_g1, Transferrin Receptor (Tfrc):
Mm0044941_m1, Megalin (Lrp2): Mm01328171_m1, 24p3R
(Slc22a1): Mm00480680_m1, and Bdh2: Mm00459075_m1. For
internal normalization we used HEX-labeled Gapdh probe:
4326317E (all from Applied Biosystems).
Elisa
Quantification of plasma LCN2 was performed by standard
ELISA techniques as described in [47] and [30] using the
following antibodies: Affinity purified goat anti-lipocalin-2 (1:500,
AF 1857, R&D Systems), biotinylated rabbit anti-lipocalin-2
(1:200, [30]), and horseradish peroxidase Avidin D (1:3000, 18–
4100, eBioscience).
Statistics
Statistical analyses were performed using GraphPad Prism 5
(GraphPad Software). To meet the requirements of parametric
tests, we log10 transformed tumor volumes. Significance was set at
p,0.05.
Results
We chose the MMTV-PyMT-model on a FVB/N background
for the study of spontaneous breast cancer development as tumor
development is very uniform and predictable with time, thus
offering minimal variation in tumor development and progression
[49,50]. The breeding strategy is shown in Figure S1. The
progression of mammary tumors was quantified as described in
Materials and Methods and the mice were sacrificed at week 13.
Figure 1 (A, C, E) shows the expression of lipocalin-2 in tumors of
MMTV-PyMT wild-type mice and MMTV-PyMT Lcn2 knock-out
mice (from now on referred to as PyMT-mice). A uniform strong
immunohistochemical staining for lipocalin-2 was observed in the
tumor cells of wild-type mice whereas no labeling was observed in
the knock-out mice. MMP-9 was observed in the few neutrophils
present and no difference was observed between wild-type and
Lcn2 knock-out mice (Figure 1 B, D, F). Histological examination
showed that all tumors except one were Late Carcinomas. The
only Early Carcinoma was from the group with lowest numbers of
metastases, indicating low malignant potential. No obvious
differences in the stroma were observed between the two groups.
In Late Carcinomas, fibrous strands of collagen tissue were seen
between tumor nodules, and tumors were otherwise surrounded
by loose connective tissue or fatty tissue. Focal squamous
differentiation was seen in one Late Carcinoma, a feature which
is not considered to alter the malignant potential. In the other Late
Carcinomas, smaller and larger cystic necroses or partly cystic
glands were seen. Hence, no difference in indices of malignancy
was observed between wild-type and knock-out mice as deter-
mined by histological examination (Figure 1 G, H and table 1).
Figure 4. Growth of metastases in PyMT, Lcn2+/+ and PyMT, Lcn22/2 mice. Lipocalin-2-deficiency has no statistical significant effect on total
volume (t-test, p = 0.09) or number (t-test, p = 0.09) of lung metastases derived from primary mammary tumors (n = 33 for PyMT, Lcn2+/+ and n = 26
for PyMT, Lcn22/2). A, volumes of lung metastases in PyMT, Lcn2+/+ and PyMT, Lcn22/2 mice. Dots at 0 indicate mice without metastases. B, total
numbers of lung metastases in PyMT, Lcn2+/+ and PyMT, Lcn22/2 mice. Horizontal bars indicate medians. Abbreviations: PyMT: MMTV-PyMT.
doi:10.1371/journal.pone.0039646.g004
Lipocalin-2 in Mouse Breast Cancer
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Moreover, we performed immunohistochemical staining for the
luminal marker E-cadherin, the myoepithelial marker alpha
smooth muscle actin (a-SMA), and the mesenchymal marker
vimentin. E-cadherin was negative in all tumors (Figure 2 A, B) but
clearly positive in adjacent normal mammary glands and
epidermis (Figure S2 A). a-SMA was also negative in all tumors,
but some positivity was seen in tumor capsule and vessel wall
(Figure 2 C, D). Normal mammary glands with myoepithelial cells
and vessel walls stained positive for a-SMA as expected (Figure S2
B). Vimentin stained positive in tumor capsule and in small
connective tissue strands between tumor nodules, but the core of
the tumor nodules was negative (Figure 2 E, F). This is
Figure 5. Quantitative real-time PCR analysis of mRNA levels in mammary tumors/glands. Expression levels of each marker are shown
relative to the value found in tumors of PyMT, Lcn2+/+ mice, which is given the value 1. The cycle threshold (Ct) value of the PyMT, Lcn2+/+ mouse
with the highest expression of each marker is: Lcn2 (Ct = 20), Mmp-9 (Ct = 34), 24p3R (Ct = 28), Tfrc (Ct = 27), and Bdh2 (Ct = 35). Data for the PyMT,
Lcn2+/+ and PyMT, Lcn22/2 mice are the mean expression in tumors of nine mice each (each measured in triplicate). Data for the Lcn2+/+ and
Lcn22/2 mice represent the mean expression in mammary glands of two mice each (each measured in triplicate). The vertical error bars represent
the standard deviations. Abbreviations: PyMT: MMTV-PyMT.
doi:10.1371/journal.pone.0039646.g005
Lipocalin-2 in Mouse Breast Cancer
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conformable with the observations performed on H+E-stained
sections where very little stroma is seen in tumors. Overall we saw
no differences in staining for E-cadherin, vimentin and a-SMA
between tumors from PyMT, Lcn2+/+ and PyMT, Lcn22/2 mice.
We next assessed the influence of lipocalin-2 on the following
parameters of tumor growth and metastases: Age at appearance of
palpable tumors, volume of primary tumors at sacrifice, number of
mammary glands involved, total volume of metastases, number of
metastases, and volume of primary tumors versus volume of
metastases.
Tumor onset occurred early in this FVB/N background mouse.
By week 5, 40% of both wild-type (14 of 33) and Lcn2 knock-out
mice (9 of 25) developed palpable tumors and by week 8 all mice
(n = 58) had palpable tumors. No statistical significant difference
was observed between the two groups of mice (Figure 3 A). The
average total tumor volume, as determined by a caliper, increased
exponentially from week 8 until sacrifice and no difference was
observed between the two groups (Figure 3 B). The same holds
true for the mammary gland pair with the least aggressive growth
rate (pair number two) and the pair with the most aggressive
growth rate (pair number one), see Figure S3. At sacrifice, the vast
majority of mice had tumors in 8 or more of the 10 mammary
glands, and again no statistical significant difference was observed
between the two groups (Figure 3 C). The uniform development of
mammary tumors in this mouse model is quite striking.
The effect of lipocalin-2 on number and total volume of
metastases was determined as described in Material and Methods.
The range, both in number of metastases and in their cumulated
volume, is very wide ranging from three mice without metastases
in the Lcn2 knock-out group to more than 300 metastases in one
wild-type mouse. No statistical significant difference was observed
between the two groups with respect to either number of
metastases or total volume of metastases (Figure 4). A significant
correlation was observed between the volume of primary tumors
and the volume of metastases (p,0.01). The same relation was
found in wild-type and Lcn2 knock-out mice (data not shown).
In order to explore any relation of tumor aggressiveness and
lipocalin-2 expression to pathways which are relevant for
mediating effects of lipocalin-2 or for compensating the lack of
lipocalin-2, we systematically investigated the mRNA levels of such
relevant proteins in samples from nine wild-type and nine Lcn2
knock-out mice. The size of tumor in the fourth left mammary
gland was determined in each mouse and three sample sets
consisting of three animals having small tumors, three with
intermediate size tumors, and three with large tumors were
selected, and mRNA extracted for quantitative real-time PCR.
Expression of mRNA for Lcn2, Mmp9, Bdh2, 24p3R, megalin
(another receptor mediating cellular uptake of lipocalin-2 [51]),
and transferrin receptor (Tfrc) were determined in each tumor and
reported as mean of all tumors/tissue samples in each of the four
groups of mice (Figure 5). The values for each of the three sample
sets for the two PyMT-positive mouse populations are given in
Figure S4. Figure 5 A shows that Lcn2 mRNA was upregulated 5
fold in tumors of PyMT, Lcn2+/+ mice compared to normal
mammary tissue of wild-type mice, whereas Mmp9 mRNA was
virtually absent from tumors, but present in normal mammary
tissue with no difference between the two groups of mice (Figure 5
B). No signal was observed for megalin (data not shown) whereas
expression of the other lipocalin-2 receptor 24p3R was detected
but showed no difference between PyMT, Lcn2+/+ and PyMT,
Lcn22/2 mice or between PyMT-positive and PyMT-negative
mice (Figure 5 C). We speculated that a compensatory increase of
the transferrin receptor might take place in the absence of
lipocalin-2. The transferrin receptor was over-expressed in tumors
compared to normal tissue, but with no significant difference
between PyMT, Lcn2+/+ and PyMT, Lcn22/2 mice (Figure 5 D).
mRNA for the enzyme BDH2, which produces 2,5-DHBA, the
recently identified mammalian siderophore ligand for lipocalin-2,
was barely detected in normal mammary tissue as estimated by the
late appearance of BDH2 in our real-time PCR, and was virtually
absent in tumors with no difference between the two groups of
mice (Figure 5 E).
In contrast to man [30], lipocalin-2 is generated by the mouse
liver as an acute phase protein [52]. We therefore expected the
level of lipocalin-2 in plasma to increase with increasing tumor
burden as a result of secretion both from the tumors and from the
liver. We did not, however, observe any statistical significant
increase with tumor burden (Figure 6).
Both previous reports on spontaneous transgenic breast cancer
in a lipocalin-2 knock-out or wild-type background [38,39] have
identified a high-molecular weight form of MMP-9. In one study
no evidence for the formation of a lipocalin-2:MMP9 complex was
found [38] whereas in the second study [39] this high-molecular
weight form of MMP-9 was interpreted as an association between
MMP-9 and lipocalin-2 and presented as a possible explanation
for the enhanced aggressiveness of the tumors expressing lipocalin-
2 as lipocalin-2 was suggested to prevent degradation of MMP-9
[39]. The latter interpretation is surprising as the formation of a
heterodimer between lipocalin-2 and MMP-9 depends on the
availability of a free cysteine in both proteins. The human
lipocalin-2, NGAL, contains three cysteines, two of which (Cys 76
and 175) are engaged in an intramolecular disulfide loop, and the
third (Cys 87) available for formation of homodimers or
heterodimers, which may involve 92 kD MMP-9 [18]. The mouse
orthologue, however, contains only the two cysteines engaged in
intramolecular disulfide loops and the mouse lipocalin-2 is
consequently unable to form both homodimers and heterodimers.
This was ascertained by western blotting of lipocalin-2 and MMP-
9 in tumors and myeloid cells under reducing and non-reducing
conditions from wild type and Lcn2 knock-out mice and compared
with human myeloid cells (Figure 7 A–D). The same molecular
weight (MW) form corresponding to LCN2 monomer is observed
in tumors and myeloid cells, indicating that there is no difference
in post translational modification of LCN2 in tumors and myeloid
cells in mice (Figure 7 C). Only monomeric LCN2 is observed in
Figure 6. Plasma-lipocalin-2 (p-LCN2) analyzed by ELISA. There
is no correlation determined by linear regression between the total
volume of mammary tumors at week 13 and p-LCN2 in PyMT, Lcn2+/+
mice, p = 0.68 (n = 27). PyMT, Lcn2+/+ mice are indicated by dots and
Lcn2+/+ mice are indicated by a square. Solid line indicates best fitted
line and dashed lines indicate 95% confidence bands. Abbreviations:
PyMT: MMTV-PyMT.
doi:10.1371/journal.pone.0039646.g006
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tumors and myeloid cells under non-reducing conditions and no
band corresponding to the LCN2:MMP-9 heterodimer was
observed. In Figure 7 D immunoreactive bands with very high
MW forms are observed in tumors from both wild type and Lcn2
knock-out. The nature of these is unknown but these cannot
represent complexes between MMP-9 and lipocalin-2 as the same
bands are observed for both wild type and lipocalin-2 knock-out
mice.
In addition, we performed zymography of mouse plasma and
tumor extracts from wild type and Lcn2 knock-out mice (Figure 8
A and B). We observed several bands with gelatinolytic activity
both in plasma and in tumor extracts, but with no difference in the
patterns between wild type and Lcn2 knock-out. No activity with a
MW higher than the MW of monomeric human MMP-9 was
observed in tumors. All gelatinolytic activity was inhibited by
EDTA and phenantroline (data not shown).
Discussion
Our results show that lipocalin-2 is dispensable for tumor
development judged by any of the parameters used for determi-
nation of the clinical aggressiveness of cancers, such as differen-
tiation grade, time to cancer development, number of mammary
glands involved, size of primary tumors, and number and size of
metastases in this mouse model of breast cancer induced by the
mouse mammary tumor virus-polyoma middle T antigen.
This is in contrast to two recent reports using much the same
approach as here to study the role of lipocalin-2 in breast cancer
development. The first report, where tumor development was
driven by the ErbB2 oncogene [39], showed both faster onset of
tumor genesis, higher primary tumor numbers, larger volume of
primary tumors, as well as a higher number of metastases and
larger volume of metastases in lipocalin-2 expressing mice. The
second report, where the tumors were driven by the polyoma-
middle T antigen as in our study, showed no effect of lipocalin-2
expression on number of metastases, but did show an effect on
number of primary tumors, the volume of primary tumors, and on
the time of onset of tumor genesis [38]. The mice used for
examining the effect of ErbB2-induced mammary tumors was
obtained by breeding Lcn22/2 (C57BL/6) mice with MMTV-
ErbB2 (FVB/N) mice. The mixed and non-homogeneous genetic
background of the offspring from the cross between the two mouse
strains (C57BL/6 and FVB/N) in combination with the smaller
sample sizes analyzed in the ErbB2-study might explain some of
the differences between the finding and the data presented here.
The other study examining PyMT-induced mammary tumors was
performed in both C57BL/6 and 129/Ola mice (both backcrossed
for at least 10 generations), while we used mice on a FVB/N
background backcrossed for 8 generations. It is possible that this
may have had an effect on the outcome. The FVB/N strain has
been demonstrated to be more susceptible than C57BL/6 with
respect to tumor genesis in the PyMT model [49,53,54]. The
FVB/N background has therefore been used by us for several
studies of mammary tumor growth and metastases because it offers
a very uniform and predictable mammary tumor development by
the tumor virus-polyoma middle T antigen [55], thus optimizing
the ability to test the effect of agents that interfere with tumor
development, in particular such that inhibit tumor growth and
metastases [44,56]. Finally, one could envision that the specific
knock-out mouse model used might influence the results. Berger
et al. used a knock-out mouse constructed by themselves [21]
Figure 7. Western blot of human granulocytes from peripheral blood, mouse granulocytes from the spleen, and tumor extracts.
Lipocalin-2 (LCN2) is unable to form a heterodimer with MMP-9 in mouse. There is no difference in the post translational modification of LCN2 in
tumors compared to myeloid cells in mouse. A, samples analyzed under non-reducing conditions. In humans the LCN2:LCN2 and the MMP-9:MMP-9
homodimers and the LCN2:MMP-9 heterodimer are identified. In addition the MMP-9 monomer is seen. In contrast no heterodimer between LCN2
and MMP-9 is seen in the mouse, only the LCN2 monomer and both the monomeric and dimeric forms of MMP-9 are seen. B, samples analyzed under
reducing conditions. The LCN2:MMP-9 heterodimer as well as the LCN2:LCN2 and MMP9:MMP9 homodimers are no longer identifiable after breakage
of disulfide bindings. Merely the LCN2 monomer and the MMP-9 monomer are identified in both humans and mouse. C, left panel, samples analyzed
under non-reducing conditions. Right panel, reducing conditions. Only the LCN2 monomer and no heterodimer is identified under both conditions.
D, left panel, samples analyzed under non-reducing conditions. The MMP-9 monomer is seen, and in some of the tumors even the homodimer is
identified. Right panel, reducing conditions. The MMP-9 monomer is seen along with high molecular weight (HMW) bands of unknown origin. The
HMW bands are seen in both PyMT, Lcn2+/+ and PyMT, Lcn22/2 mice and therefore cannot be the lipocalin-2:MMP-9 heterodimer. All blots are
shown in full-length size. Samples are loaded in the same order in C and D as in Figure 8. Abbreviations: WT and KO tumors: Tumors from PyMT,
Lcn2+/+ or PyMT, Lcn22/2 mice respectively. Gr-1+: Gr-1 positive cells purified from the spleen of two FVB/N mice.
doi:10.1371/journal.pone.0039646.g007
Figure 8. Gelatin zymography of MMP-9 activity. No difference in
gelatinolytic activity is observed between PyMT, Lcn2+/+ and PyMT,
Lcn22/2 mice, either in tumors or in plasma. A, zymography of tumors
from PyMT, Lcn2+/+ (WT) and PyMT, Lcn22/2 (KO) mice with purified
human MMP-9 (hMMP-9) as standard [2]. B, zymography of plasma from
WT and KO mice along with human plasma and a molecular weight
standard. Tumor and plasma samples from mice are loaded in the same
order as in Figure 7 C and D.
doi:10.1371/journal.pone.0039646.g008
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while the Lcn2 knock-out mouse used in the Leng study and by us
is developed by Aderem and Akira [20].
There are multiple possible reasons for our observation of the
lack of effect of lipocalin-2 in the face of several other studies
indicating the contrary. It is possible that the growth potential of
the tumor cells and their propensity for metastasis in our model is
so strong that it overrides a modulating effect of lipocalin-2.
Tumor genesis occurred very early in our study as all mice had
palpable tumors by day 56 versus only 10% mice with palpable
tumors on day 56 in the PyMT model by Berger et al [38]. Tumors
appeared even later in the ErbB2 mouse (100% tumor free day
160) [39]. Thus, it seems that the largest effect of lipocalin-2 on
tumor development and aggressiveness is observed in the mouse
model with the slowest onset of tumor genesis, the ErbB2 mouse. A
contributing factor to the difference could be that the ErbB2 and
PyMT oncogenes work through different signaling pathways
[39,50]. We do, however, consider it unlikely that the effect of
lipocalin-2 diminishes with the aggressiveness of the tumors if
lipocalin-2 promotes tumor growth by offering iron for cell
division, as such effect would not be overruled by a strong intrinsic
drive for cell division and metastasis. In fact the contrary would be
expected, i.e. a high sensitivity towards deprivation of lipocalin-2.
We also believe that the high number of animals in each arm of
our cohort and the relatively minor variation in the two groups
would allow even minor effects of lipocalin-2 to be picked up.
Another explanation would be that the expression of lipocalin-2
in mammary tumors is significantly lower in our study than the
expression in the mammary tumors in the two other reports. While
we do not have any data to allow a direct comparison, the
expression of lipocalin-2 was certainly pronounced in the
mammary tumors in our study as seen in Figure 1 and as
indicated by the quantitative mRNA data (Figure 5). Yet another
explanation could be that lipocalin-2 cannot be utilized properly
by the tumor cells in our mouse system. While the lipocalin-2
receptor megalin was absent, 24p3R mRNA was expressed in the
tumors allowing for a possible uptake of lipocalin-2 in these cells.
We did, however, only obtain a very weak signal for mRNA for
enzyme BDH2 that catalyzes the synthesis of 2,5-DHBA, which
renders it unlikely that this mammalian siderophore is involved in
iron homeostasis of these cells. This could explain why the lack of
lipocalin-2 production in our knock-out mice did not have any
effect on mammary cancer development in the FVB/N mouse
strain. Whether the expression of the lipocalin-2 receptors and
BDH2 is similar in the C57BL/6 and 129/Ola strains used in the
other studies is not known, as no report of this was given in the
studies.
It is well established that the different genetic backgrounds of
the FVB/N and C57BL/6 mouse strains can affect the outcome of
a genetic ablation on cancer development as exemplified in the
Mmp-9 [54] and iNOS [53] knock-out models. This may also be the
case with lipocalin-2 indicating that the effect of Lcn2 on cancer
development is dependent on the genetic setting of the individual
organism.
Another mechanism by which lipocalin-2 can convey a
metastatic potential to tumor cells has been proposed to relate to
the possible activating or stabilizing effect of lipocalin-2 on MMP-
9 [34,57]. However, our data do not support such a mechanism.
First, we did not observe any enhanced expression of MMP-9 in
the lipocalin-2 expressing mice. Second, we show that mouse
lipocalin-2, in contrast to the human orthologue, lacks the ability
to form a covalent bond with MMP-9 and hence does not have the
potential to mediate MMP-9 activation or inhibited degradation of
MMP-9 as has been inferred. This is also in agreement with our
findings on zymography. Our investigation therefore leads us to
conclude that the role of lipocalin-2 in breast cancer progression is
questionable.
Supporting Information
Figure S1 Breeding strategy used for generating the
mice used in the experiments. Congenic heterozygous male
FVB/N-MMTV-PyMT mice were mated with female FVB/N-
Lcn2+/2 mice back-crossed to the FVB/N strain for 8 generations
(N8). Their male FVB/N-PyMT, Lcn2+/2 offspring (F1) were
mated with FVB/N-Lcn2+/2 (N9) females to generate the FVB/
N-PyMT, Lcn2+/+; FVB/N-PyMT, Lcn22/2; FVB/N Lcn2+/+,
and FVB/N, Lcn22/2 mice used throughout the study.
Abbreviations: PyMT: MMTV-PyMT.
(TIF)
Figure S2 Positive control stainings for E-cadherin and
a-SMA. A, E-cadherin staining of the dermis and epidermis of a
PyMT, Lcn2+/+ mouse as positive control to Figure 2 A, B.
Original magnification x400. B, a-SMA staining of a primary
tumor and adjacent vessels of a PyMT, Lcn2+/+ mouse as positive
control to Figure 2 C, D. Original magnification x200.
Abbreviations: PyMT: MMTV-PyMT.
(TIF)
Figure S3 Tumor growth of the fastest and the slowest
growing mammary gland pairs in PyMT, Lcn2+/+ and
PyMT, Lcn22/2 mice. A, average of tumor volume in gland
pair number one versus mouse age. B, average of tumor volume in
gland pair number two versus mouse age. No statistical significant
difference between PyMT, Lcn2+/+ and PyMT, Lcn22/2 mice at
week 13, t-test after logarithmic transformation, p = 0.60 for gland
pair number one and p = 0.51 for gland pair number two (n = 29
for PyMT, Lcn2+/+ and n = 20 for PyMT, Lcn22/2).
(TIF)
Figure S4 Quantitative real-time PCR analysis of mRNA
levels in mammary tumors/glands. A, Lcn2. B, Mmp9. C,
24p3R. D, Tfrc. E, Bdh2. The vertical error bars represent
standard deviations. The mean expressions are shown in three
PyMT, Lcn2+/+ mice with small tumors (1), three with
intermediate size tumors (2) and three with large tumors (3), and
the mean expressions are shown in three PyMT, Lcn2-/- mice with
small tumors (4), three with intermediate size tumors (5) and three
with large tumors (6) located to the fourth mammary gland on the
left hand side. The PyMT negative mice were selected randomly
and number (7) and (8) represent two mice each. Expression levels
of each marker are shown relative to the value found in small
tumors of PyMT, Lcn2+/+ mice, which is given the value 1. Tumor
volumes: 1) 0.07 cm3, 0.15 cm3, 0.17 cm3 2) 0.47 cm3, 0.55 cm3,
0.68 cm3 3) 0.82 cm3, 0.98 cm3, 1.50 cm3, 4) 0.02 cm3, 0.08 cm3,
0.09 cm3 5) 0.50 cm3, 0.54 cm3, 0.63 cm3 6) 0.73 cm3, 0.98 cm3,
1.33 cm3 Abbreviations: PyMT: MMTV-PyMT.
(TIF)
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